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The Hepatitis C virus (HCV) is a major public
health problem and the most common cause
of death from liver disease in the United
States.1 According to population-based stud-
ies, HCV accounts for more than 40% of
chronic liver disease in the U.S., and causes
about 10,000 deaths per year.2 Although the
proportion of these deaths that occur in cor-
rectional facilities is believed by many to be as
high as 30% and rising, the exact numbers of
deaths due to HCV that occur in the U.S. cor-
rectional system is
unknown. Despite the
declining incidence of
HCV infection, the preva-
lence of HCV-related
chronic liver disease is
increasing because of a
substantial time lag
between infection and
clinical manifestations.
Although the estimated
prevalence of hepatitis C
in the U.S. is about 2%,3
it is significantly higher in state and federal cor-
rectional facilities (16-49%).4-6 According to a
U.S. Justice Department study, 1.3 to 1.4 mil-
lion inmates released from prison in 1996 were
infected with HCV, or about 30% of the total in
the U.S. population with the condition.7 As in
the general population, injection drug use
(IDU) accounts for most HCV infections in the
correctional setting, as up to two-thirds of
inmates have a history of IDU before incarcer-
ation.5 Since there is such a high prevalence of
HCV among inmates, the correctional environ-
ment affords an opportunity to diagnose and
treat the virus in many of those who are
infected.  
The following topics are among the most
important in the realm of HCV treatment as
published in medical literature or presented at
scientific meetings in the past two years. For
more essentials on HCV epidemiology, natural
history and treatment, the reader is
encouraged to consult prior issues of HEPP
Report.8-10
Early Virologic Response
The best therapy currently available for treat-
ment-naïve patients is weekly injections of
pegylated-interferon alpha-2a coupled with
twice daily oral ribavirin. Sustained virologic
response (SVR is
defined as unde-
tectable HCV RNA 24
weeks after the com-
pletion of therapy) can
be achieved in more
than half of those
treated.11-12 However,
early identification of
treatment non-respon-
ders is warranted to
spare the expense
and side effects of
unnecessary medica-
tion. Consequently, the use of the early viro-
logic response (EVR) has been popularized. 
The best marker of EVR in terms of sensitivity
(capture the largest number of responders)
and negative predictive value (eliminate the
largest number of non-responders) is a decline
in the HCV viral load of at least 2-log from
baseline after 12 weeks of therapy. Patients
not achieving this treatment milestone have
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almost no chance of achieving a SVR,13
and therefore can be spared an additional
12 to 36 weeks of unnecessary therapy. In
a recently published economic analysis,
the use of EVR decreased costs by 45%
when compared to a full course of thera-
py.14 Based on these data, many experts
recommend terminating therapy for
patients who do not reach an EVR at 12
weeks.
There are several caveats to bear in mind
when utilizing EVR. Because most
patients with genotypes other than 1
achieve an EVR, using a 12-week cut-off
reduces costs only marginally in patients
with other genotypes.13 Secondly, varia-
tions of up to one 1 log unit can occur with
any assay, so a patient with a 1.8-log RNA
drop at 12 weeks, for example, may still
achieve a sustained response.15
Moreover, histologic benefits may be
achieved despite patients not reaching
early or sustained virologic responses.16
Although many insurance companies
have justified stopping coverage of med-
ications for patients who do not reach this
threshold, a patient may still show signifi-
cant hepatic histologic improvement or at
least delayed histologic progression with-
out reaching an EVR/SVR. This topic will
be discussed in greater detail below.
Accordingly, use of EVR should be viewed
as an individualized tool and not a hard
and fast rule for terminating therapy. 
Persistently Normal
Aminotransferases (PNALT)
HCV is usually associated with elevated
alanine aminotransferase (ALT) levels, yet
about 30% of patients with chronic HCV
have persistently normal ALT levels.17
The study of this patient subset has been
compounded by differing definitions of a
"normal" ALT.18,19 The definition of a nor-
mal ALT used in the phase III clinical trial
of peginterferon alfa-2b and ribavirin was
<43 IU/L for men and <34 IU/L for
women.11 Patients with PNALT were
defined as those with three separate
blood tests drawn at least one month
apart that demonstrated ALT measure-
ment at or below the upper limit of the nor-
mal level. 
Although many patients with PNALT have
a slow progression of fibrosis,20 some
PNALT patients have relatively advanced
fibrosis on liver biopsies.21 In a recent
study of 91 HCV RNA-positive patients
with PNALT (all of whom had liver biopsy),
one in six patients had significant, pro-
gressive liver disease that was only iden-
tified on liver biopsy.22
Treatment for the HCV patient with
PNALT has been controversial. An older
study of interferon monotherapy for those
with PNALT showed that therapy caused
elevations in ALT, and was therefore not
beneficial.23 However, subsequent studies
treating those with PNALT using standard
interferon/ribavirin showed sustained
response rates without ALT "flares" in
47% of the patients.24,25
The 2002 NIH Consensus Guidelines on
the Management of HCV recommended
that treatment for HCV patients with
PNALT should be individualized, taking
into account factors such as liver histol-
ogy, HCV genotype, patient age, motiva-
tion for therapy and co-morbid condi-
tions.26 A recently completed multicenter,
multinational, randomized trial showed
that HCV-infected PNALT patients had
similar rates of sustained response
compared to those with elevated ALTs
when treated with pegylated-
interferon/ribavirin.27
In a recent study by Ghany, et al., 123
patients with chronic HCV underwent two
liver biopsies, each at extended, but vari-
able intervals. The biopsy reports were
correlated with serum aminotransferases.
The authors concluded that the best pre-
dictors of fibrosis progression in these
patients were the extent of serum amino-
transferase elevations and the degree of
hepatocellular necrosis and inflammation
on liver biopsy.  Consequently, they felt
these findings support the recommenda-
tion that patients with PNALT and mild
liver histology can safely defer treat-
ment.28 As a result of these studies and
others, some specialists believe that all
PNALT patients who are otherwise candi-
dates for treatment should undergo liver
biopsy, and that treatment should be
based on histology results. 
Liver Biopsy
The necessity of liver biopsy prior to treat-
ment is also a subject of debate. Despite
drawbacks like the potential for complica-
tions and sampling error, biopsy is the
only reliable predictor of natural history of
disease.29,30 Nearly all patients with high-
grade necroinflammation and most of
patients with intermediate-grade on biop-
sy develop cirrhosis.31 Nonetheless, the
cost-effectiveness of treating patients
without fibrosis on biopsy has been ques-
tioned.32 Expert consensus groups from
the U.S. and Europe have previously rec-
ommended the routine performance of
liver biopsy prior to antiviral therapy initia-
tion.33,34 However, recent guidelines from
the American Association for the Study of
Liver Diseases (AASLD) are less dogmat-
ic: "biopsy is not mandatory to initiate ther-
apy…yet a liver biopsy should be done
when results will influence the recommen-
dation to treat".35
Different prison systems take different
approaches to liver biopsy. The Federal
Bureau of Prisons, Louisiana, and
Georgia require a biopsy prior to treat-
ment, and only treat those with significant
fibrosis. On the other hand, Texas and
Pennsylvania systems do not mandate
biopsy for those who desire treatment and
do not have contraindications.36 A recent
cost-effectiveness study of HCV-infected
inmates was carried out at the Louisiana
State Penitentiary in which 501 patients
were evaluated, approximately half of
whom had pre-treatment liver biopsies. In
an analysis of those patients infected with
HCV genotype 1 who received pegylated-
interferon/ribavirin, the cost of HCV treat-
ment was $16,826 per patient treated with
liver biopsy and $14,389 for those treated
without liver biopsy. The authors conclud-
ed that a protocol using liver biopsy as a
means to determine eligibility for therapy
does in fact balance costs and complies
with current recommendations.37
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3Cirrhosis and Maintenance
Therapy
Patients with HCV-related cirrhosis have a
high risk of dying from end-stage liver dis-
ease (30% over 10 years35), and thus
have much to gain from successful treat-
ment. Patients with advanced liver dis-
ease can be successfully treated with
interferon-based therapies, but sustained
response rates are lower and medication
dose reductions are needed more fre-
quently in this population relative to those
with less advanced disease. 
Most of the data supporting the treatment
of compensated cirrhotics comes from
subgroup analysis of larger trials in which
43% of those treated with pegylated-inter-
feron/ribavirin achieve an SVR.11,12 Only
one published treatment trial examined
patients with advanced liver disease
exclusively; cirrhotic patients on pegylat-
ed-interferon monotherapy achieved an
SVR in 30% of cases.38 In patients who
achieve SVR, the risk of developing hepa-
tocellular carcinoma or liver failure may
also be diminished.39
Despite some data supporting the treat-
ment of compensated cirrhotics, there is
little evidence supporting therapy for those
with decompensated liver disease
(ascites, encephalopathy, etc.). These
patients should be referred to liver trans-
plantation centers or be enrolled in clinical
trials (See HEPP ReportDecember 2003
issue at www.hivcorrections.org for the
management of decompensated liver
patients in the correctional setting.).
Even if patients do not achieve an SVR,
both cirrhotics and non-cirrhotics may still
have significant hepatic histologic
improvement or at least delayed histolog-
ic progression following treatment with
combination therapy. In an analysis of
data from over 3,000 patients receiving
sequential liver biopsies, interferon-based
treatment reduced the rate of fibrosis pro-
gression. Despite only a third of patients
achieving SVR, nearly half had reversal of
their cirrhosis. 73% of patients had
improvement of necrosis and inflamma-
tion, irrespective of achieving SVR.18 In a
more recent meta-analysis of over 1,000
treatment-naïve patients, pegylated-inter-
feron alfa-2a significantly reduced fibrosis
relative to standard interferon.40
Based upon the above two studies and
others like them, some specialists support
the concept of "maintenance therapy" in
which patients with cirrhosis who do not
achieve an SVR continue therapy in
hopes of achieving a regression or slow-
ing of their liver disease. Although many
providers are utilizing maintenance thera-
py in their practices, this approach  is still
experimental since it has not been proven
in well-controlled trials. Large multi-center
trials such as HALT-C, COPILOT and
EPIC are underway and will likely provide
guidance on this issue.
HCV and HIV Co-infection
HCV is common in HIV-infected patients
because of shared routes of transmission.
In fact, the U.S. Public Health Service and
the Infectious Disease Society of America
advocate screening all HIV-infected indi-
viduals for HCV.41 HIV seropositivity accel-
erates the rate of HCV-progression by
about three-fold.42
Many providers are treating co-infected
patients for both diseases. The more
intact the immune system (CD4+ count
>200 cells/mm3), the higher likelihood of
sustained response to HCV therapy.43
Several authors have recommended liver
biopsy prior to initiating treatment for HCV
in co-infected patients.44 Co-infected
patients should be monitored closely
because the concomitant use of nucleo-
side analogs and ribavirin increases the
risk of pancreatitis, anemia and lactic aci-
dosis.45-47 Furthermore, ribavirin is con-
traindicated with didanosine (ddI) since it
increases risks of side effects associated
with ddI. Finally, the potential for antiretro-
viral medication-induced hepatotoxicity is
compounded in HCV-infected patients.
The results of recently completed trials of
over 400 co-infected patients treated with
pegylated-interferon alfa-2a/ribavirin have
been made available. Sustained response
rates ranged from 27 to 40%, yet discon-
tinuation rates ranged from 12 to 25%.48-50
Both response rates and termination rates
are significantly higher when compared to
those from monoinfected HCV patients.
However, in co-infected patients, the rates
of SVR are better with treatment with
pegylated-interferon alfa-2a than with
treatment with standard non-pegylated
interferon alpha-2a/ribavirin.
African-Americans and
Hepatitis C
Compared with Caucasians, U.S. minority
populations are disproportionately affect-
ed by chronic HCV infection.3
Furthermore, African-Americans are more
likely to be infected with HCV genotype 1
and develop chronic infection than are
Caucasians.51,52Efforts to assess the nat-
ural history of HCV-infected African-
Americans have been hampered by inad-
equate representation of African-
Americans in HCV prospective trials. A
retrospective study of over 350 patients
showed that African-Americans had signif-
icantly less necrosis and cirrhosis on liver
biopsy compared to Caucasians.53
However, another retrospective analysis
of over 300 inmates from the Virginia
Department of Corrections showed there
were no clinically significant differences
between Caucasians and African-
Americans on liver biopsy.54 Nonetheless,
African-Americans with HCV-related cir-
rhosis may have up to a six times higher
risk of developing hepatocellular carcino-
ma compared to their cirrhotic Caucasian
counterparts.55
With respect to interferon-based therapy,
most studies have reported lower
response rates among African-Americans
compared to Caucasians. Ongoing stud-
ies of standard interferon/ribavirin combi-
nation therapy have shown lower sus-
tained responses in African-Americans
compared to Caucasians.56,57 The lower
response rate may be due, in part, to an
impaired ability of African-Americans to
inhibit viral production and clear virus with
therapy,58 but the reason for the dis-
crepant response rates are still unclear.  
Preliminary results are available from the
first well-controlled clinical trial conducted
exclusively in African-Americans infected
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with genotype 1. This trial evaluated the
safety and efficacy of pegylated-interferon
alpha-2a/ribavirin treatment. When com-
pared to the historical control group
(genotype 1 patients of similar weight to
those in the study), there was a lower rate
of SVR, 26% versus 39%, respectively, for
the trial participants and controls. The util-
ity of EVR was confirmed in this popula-
tion; i.e. EVR had a good negative predic-
tive value in both studies involving
African-Americans and non-African-
Americans. Although no unexpected
adverse effects were noted in this trial,
African-Americans in this trial developed
more neutropenia than did controls.59 For
unknown reasons, the significance of neu-
tropenia-related treatment was less clini-
cally significant than previously thought,
especially in African-Americans.60 Finally,
the study showed that even the patients
without an SVR achieved a benefit with
respect to hepatic histology.61 In summa-
ry, although the likelihood of an SVR is
decreased among African-Americans, are
less than those of non-African-Americans,
HCV treatment may be beneficial, and
ethnicity should not be a  criterion on
which to base suitability of  therapy.
Since there is such a high prevalence of
HCV among inmates, the correctional
environment affords an opportunity to
diagnose and treat the virus in many of
those who are infected. In this month's
Spotlight (David Thomas, J.D., MD) dis-
cusses the complex medical, legal, and
financial issues surrounding HCV treat-
ment in prisons and jails. The absence of
any formal guidelines for treatment of
HCV in correctional settings remains the
most significant roadblock to providing
good care to all HCV-infected inmates.
The time is ripe for either the Society for
Correctional Physicians or the National
Commission on Correctional Health Care
to develop these much-needed bench-
mark standards. 
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Dear Correctional Colleagues:
An estimated two million Americans are infected with hepatitis C, which now accounts for more
than 40% of chronic liver disease in the U.S. and causes about 10,000 deaths per year. In jails
and prisons, the prevalence of HCV is ten to twenty times higher than that in the free population,
and an estimated one-third of all HCV-infected Americans have spent time in jail or prison. By all
measures, correctional health care systems are bearing the brunt of the responsibility for
responding to this nation's HCV epidemic. The financial aspects of this responsibility are over-
whelming. Many correctional departments are faced with difficult decisions concerning allocation
of inadequate resources.  
Essential components of a comprehensive response to HCV should include:
– Education of at-risk persons about the importance of knowing their HCV serostatus
– Harm reduction education of at-risk individuals on how to prevent transmission of the virus 
– Vaccination of hepatitis A and B non-immune individuals to protect them from further liver injury
– Alcohol and substance abuse treatment for those in need
– Treatment of those HCV-infected persons who are most likely to benefit 
Some correctional health care programs have attempted to implement targeted HCV testing
based upon risk assessment histories. As this month's HIV 101 demonstrates, virtually all
inmates fall into a risk group for which HCV testing would be recommended (individuals with
abnormal alanine aminotransferase levels, those who have had more than 10 lifetime sex part-
ners, those who have had a history of a sexually transmitted disease, injection-drug users, and
men who have had sex with men.) Therefore, rather than attempting to coordinate risk-based
screening, it is likely to be more cost-effective to simply offer testing for HAV, HBV, and HCV to
all individuals whose serostatus is unknown.  
This month, Drs. Brian L. Pearlman and Joseph E. Paris provide a review of current HCV issues
including early viral response, management of those with persistently normal transaminases, the
role of the liver biopsy, management of HIV co-infected persons, and treatment outcomes based
upon racial background. In this month's spotlight, Dr. David Thomas reviews HCV treatment from
public health, legal, ethical, risk/benefit, and patient responsibility perspectives. 
In an effort to reflect the broad spectrum of infectious diseases that impact the correctional set-
ting, HEPP Report will soon be changing its name to IDCR: Infectious Diseases in
Corrections Report. The print and online versions will continue to provide the same up-to-date
information but in a more reader- and user-friendly format. We encourage our readers to share
their opinions on both the content and new appearance of the newsletter. 
Sincerely, 
Joe Bick, MD
Letter from the Editor
June 2004     Volume 7, Issue 6 visit HEPP Report online at www.hivcorrections.org
6The difficult question of if and when to treat those infected with
Hepatitis C Virus (HCV) can be evaluated from a myriad of per-
spectives, including public health concerns, risk/benefit in correc-
tions, legal issues, ethical issues, and personal physician-patient
responsibility. The discussion that follows reflects the opinions of
the author. 
Public Health Concerns
1. There is no clinical test for HCV disease risk to determine which
of the 2.5 to 4 million HCV-infected people in the U.S. will devel-
op liver failure or hepatocellular carcinoma, and therefore, are
most in need of treatment. 
2. Some of those who are infected may continue to participate in
activities that put them at high risk for reinfection.  
3. Most individuals (80%) do not develop complications from HCV
infection.
4. HCV mutates easily, making it unlikely that a vaccine will be
developed in the near future. 
Reflecting these concerns, public health resources have been
directed to the prevention of infection and disease. The goals of
the National Hepatitis C Prevention Strategy are "to lower the inci-
dence of acute hepatitis C in the United States and reduce the
disease burden from chronic HCV infection," through:  
1) Harm reduction programs directed at persons at increased risk
for infection to reduce the incidence of new HCV infections; 
2) Counseling, testing, and medical evaluation and management
of infected persons to control HCV-related chronic liver disease; 
3) Surveillance to evaluate the effectiveness of prevention
activities; 
4) Research aimed at prevention and control of HCV.1
Risk/Benefit to Correctional Healthcare
systems
Up to one third of those with HCV in this country have been incar-
cerated. Correctional health care workers see two discrete HCV
epidemics in prisons and jails–one that is decades old and the
other that is comprised of "rapid progressors, i.e. patients who
have not been infected for the traditional two to three decades
that are required to show problems with this disease." 2 HIV has
a clear role in the more rapid progression of HCV disease in co-
infected patients. In some prison systems, HCV has become the
single largest cause of death,3 reminiscent of the situation of HIV
a decade ago. 
Although prisoners have a constitutional right to healthcare, cor-
rectional healthcare standards vary significantly from state to
state. Some argue that to treat HCV aggressively would draw
scarce resources away from other essential correctional health-
care programs. Prison budgets are at the whim of the respective
state legislatures (and the U.S. Congress in the federal system),
and must compete with all other healthcare initiatives. Few states
have appropriated recurring funding for HCV care as they have for
the treatment of HIV. Some prison systems have chosen to ignore
the issue because with an average length of stay of less than
three years,4 it is unlikely that while incarcerated, a patient with
HCV will develop sequelae that will lead to an economic burden
for the penal system.
However, some large systems, particularly in the South, have
average lengths of stays that approach a decade.5 These systems
are more likely to face the economic consequences of therapeu-
tic nihilism. Paradoxically, most of these systems have been
among the least aggressive when it comes to HCV treatment.
Legal Issues
There are currently pending lawsuits involving correctional facili-
ties concerning failure to treat HCV;6 most of these cases are pro-
gressing at a very slow pace. It is still unclear whether or not the
plaintiffs will prevail in these cases. Last year at the "Management
of Hepatitis C in Prisons 2003" meeting (San Antonio, TX), health-
care providers discussed various approaches to developing effec-
tiv  guidelines for HCV treatment in corrections but failed to
achieve a definitive consensus on management of this infection.7
It is therefore unlikely that the courts will intervene and require a
particular approach to treatment.  
One area in which correctional systems may be vulnerable is by
requiring an inmate to have a specific amount of time left on their
sentence to be considered for treatment. The justification for this
requirement has been that it is necessary to allow the patient to
be able to complete a full course of therapy prior to release. In the
ame way that one cannot withhold cancer treatment because the
regimen may not be completed prior to discharge, there is a
requirement to initiate treatment for eligible patients and then refer
the patient to non-correctional resources once the inmate has
reached the end-of-sentence. In this sense, requiring a specific
period of time left to serve may be more legally risky than having
a policy of not treating HCV at all.
Ethical Issues
Systems that have policies that do not offer treatment for
HCV claim:
1. The natural history of the disease is not well-studied because
we have interfered in a disease process before we have truly
worked out the natural history;
2. The morbidity of treatment for treatment is very high;
3. Risk of re-infection is very high unless the patient modifies
his/her behavior;
4. The long-term effects of treatment and repeated treatment is
unknown;
5. Waiting until there are better drugs available is a better course
for the protection of our patients;
6. Of the patients who undergo therapy, it is not possible to pre-
dict those who will have a long-term benefit and those who will
not;
7. Using scarce resources on patients for whom treatment bene-
fits are uncertain leaves fewer resources for other patients who
may be in greater need or have better documented response to
therapy.
Systems with policies for treatment of HCV in place claim:
1. Some people may be cured by treatment;
2. It is unethical to withhold treatment simply because the patient
will not comply with the physician's directive (e.g. diabetics who
do not remain on a diet);
3. The morbidity of treatment is very low;
4. Cost concerns should not play a role in our decision to advo-
cate for our patients;
5. The correctional setting is the ideal setting in which to reduce
the impact of this disease because illicit drug use is probably less
than outside the correctional setting and patients generally will
complete a regimen.
David Thomas*, MD, J.D., Chair, Department of Surgery, Division of Correctional Medicine, NovaSoutheastern University, College of Osteopathic
Medicine
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7Persons with hemophilia treated with products made before 1987 
Injecting drug users 
current 
history of prior use 
Persons with abnormal alanine aminotransferase levels 
Chronic hemodialysis patients 
Persons with multiple sex partners (lifetime) 
>50 
10-49
2-9 
Persons reporting a history of sexually transmitted diseases 
Persons receiving blood transfusions before 1990
Infants born to infected mothers 
Men who have sex with men
General population
Healthcare workers 
Pregnant women 
Military personnel 
Volunteer blood donors
%
87
79
No Data
15
10
9
3
2
6
6
5
4
1.8
1
1
0.3
0.16
(range, %)
(74-90)
(72-86)
- -
(10-18)
(0-64)
(6-16)
(3-4)
(1-2)
(1-10)
(5-9)
(0-25)
(2-18)
(1.5-2.3)
(1-2)
- -
(0.2-0.4)
- -
Prevalence of persons
with characteristic, % 
<0.01
0.5
5
5
0.1
4
22
52
17
6
0.1
5
NA*
9
1.5
0.5
5
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HCV-infection prevalence
HCV 101: Prevalence of Hepatitis C Virus in the United States
The following table is adapted from the Centers for Disease Control and Prevention's HCV web-based training course Hepatitis C: What
Clinicians and Other Health Professionals Need to Know. The text is based upon the Recommendations for Prevention and Control of
Hepatitis C Virus (HCV) Infection and HCV-related Chronic Disease*
*Centers for Disease Control and Prevention.  MMWR 1998; 47 (No. RR-19)
TABLE 1. Estimated average prevalence of hepatitis C virus (HCV) infection in the United States by various 
characteristics and estimated prevalence of persons with these characteristics in the population.
*Not applicable
As with most ethical dilemmas, all sides have compelling argu-
ments. In addition, most issues fall into grey areas.  
Personal Physician/Patient Responsibility
Irrespective of our practice setting, each of us has a responsibility
to our individual patients. This responsibility exceeds that of "what
is good for most of the population." This unique relationship is one
reason why physicians understand the global problem of antibiotic
overuse, but continue to excessively prescribe in their own prac-
tices. The legal issues notwithstanding, (which in the correctional
setting include malpractice and licensure actions, as well as alle-
gations of deliberate indifference and Civil Rights infraction) there
is the matter of patient trust. Your patient expects you to do what
is best for him or her. Your final decision is based on your back-
ground of knowledge, your ethical framework and the interaction
between you and your patient at that particular moment in time.
This kind of subjectivity is the nemesis of managed care compa-
nies.  As physicians, we claim it is part of the art of medicine. It is
one of the major reasons there is not uniformity of decision-mak-
ing among physicians or, more importantly, even for a single
physician seeing patients with similar problems. Most of us would
comfortably say medicine is an art as well as a science and explain
it that way. Should it not be our unique physician/patient relation-
ship that determines whether to treat or not to treat? After all, it is
our name on the prescription and our irrevocable, non-delegable
responsibility for the patient. 
Disclosures:
*Nothing to disclose.
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National HIV Testing Day
(NHTD) 
June 27, 2004
Nationwide
Calll: (202) 464-5652
Email: pfeldman@napwa.org
Visit: www.nhtd.org
2004 Annual Conference on
Antimicrobial Resistance
June 28 - 30, 2004
Bethesda, MD
Call: (301) 656 0003 x19
Fax: (301) 907 0878
Email: scooper-kerr@nfid.org
Visit: www.nfid.org/conferences/
resistance04/ 
XV International AIDS
Conference
July 11 - 16, 2004
Bangkok, Thailand
Visit: www.aids2004.org/
Centerforce 5th Annual
Inside/Out Summit 
September 11-15, 2004 
San Francisco Airport Marriott,
Burlingame, CA
Contact: Beth Houghton
Call: 415-456-9980 x124
Visit: www.centerforce.org/
summit
Infectious Disease Society of
America
September 30 - October 3, 2004
Boston, MA
Early preregistration deadline is
July 7. Regular Registration
Deadline is August 26.
Visit: www.idsociety.org
44th Annual ICAAC
October 30 - November 2, 2004
Washington, DC
Discounted preregistration 
deadline is August 27. Final
Preregistration deadline is
September 24.
Visit: www.asm.org
National Conference on
Correctional Health Care
November 13 - 17, 2004
New Orleans, LA
Tel: 773.880.1460
Visit: www.ncchc.org
Save the 
Dates
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FDA Approves Viracept®625 mg Tablets 
The Food and Drug Administration recently
approved a new alternate dosing formulation of
Viracept®(nelfinavir mesylate). The new formu-
lation of 625 mg reduces the pill burden from
five 250 mg tablets bid to two 625 mg tablets
bid, potentially facilitating adherence to treat-
ment regimens. It is recommeded that
Viracept® be taken with a meal. Both retail and
correctional pharmacies will have the product in
stock as of June 1, 2004. 
www.viracept.com
National HCV/HIV Coinfection Coalition
Meets Capitol Hill
HEPP Reportwas among the several HCV/HIV
coinfection advocacy groups represented at the
National HIV/Hepatitis C Coinfection Coalition's
first round of visits to key House and Senate
members on April 6 and 7, 2004. At the core of
the Coalition's message was increased funding
for programs that address the specific needs of
coinfected individuals. Incorporating specific
language on HCV/HIV coinfection into the Ryan
White Care Act (RWCA) was identified by the
Coalition as the most effective vehicle for attain-
ing this goal. The Coalition also advocated for
available funding for testing, the implementation
of an effective referral system for co-infected
patients, and increased funding for ADAPs
(AIDS Drug Assistance Programs) so they can
incorporate drugs to treat co-infection into their
formularies. It is estimated that 30% of the
900,000 HIV-infected individuals are co-infected
with HCV, and this percentage is projected to be
higher among those who access ADAP funding.
Furthermore, it is estimated that 60-90% of
those who acquired HIV through intravenous
drug use are also HCV-infected. While ADAP
does not cover incarcerated patients, the out-
come of this issue will certainly have serious
implications for the thousands of co-infected
inmates released each year. While individual
members of Congress supported the Coalition's
arguments, the question of finding the money
was a recurring issue for some. The outcome of
the Coalition's efforts will be decided when
RWCA comes up for reauthorization by the U.S.
Congress later this year, marking the third round
of negotiations for reauthorization of the gov-
ernment's landmark legislation dealing specifi-
cally with HIV/AIDS care. 
Julia Noguchi, Managing Editor, HEPP Report
HAART with PI Less Likely to Show Liver
Fibrosis
In a cross-sectional Spanish study of HIV/HCV
coinfected patients from a cohort of HIV-infect-
ed patients, authors found that the use of
HAART regimens including nevirapine is asso-
ciated with an increased degree of liver fibrosis
in HIV-infected patients with chronic HCV.
Toxicity related to nevirapine can include either
an early idiosyncratic reaction or a late-onset
cumulative toxicity, both of which might be impli-
cated in the worsening liver fibrosis among HIV-
inf cted patients with chronic HCV. Patients
receiving a protease inhibitor (PI) were less like-
ly to show liver fibrosis. The results of this study
suggest that HAART including a PI may be
more advantageous in terms liver fibrosis pro-
gression than nevirapine-based regimens in
HCV co-infected persons. The associations
found in this study have not been confirmed by
randomized prospective studies with hard clini-
cal end-points, such as development of decom-
pensated cirrhosis or death attributable to liver
failure. Macías, Juana et al. AIDS: Volume 18(5)
26 March 2004 pp 767-774.
Undetectable HIV Viral Load Slows Liver
Disease Progression in HCV-HIV 
Co-infection
As reported at the European Association for the
Study of the Liver Conference (EASL) - Berlin,
Germany, April 14-18, 2004, HCV-HIV co-infect-
ed patients with suppressed HIV RNA (<400
copies/ml) have a similar rate of fibrosis as HIV-
negative patients with HCV. Co-infected
patients with uncontrolled HIV viremia have
more rapid fibrosis rates than both patients with
suppressed HIV RNA and those who are HIV-
negative. In co-infection, the rate of fibrosis is
independently predicted by log HIV viral load,
Ishak necro inflammatory score, and age at
HCV infection; and not by CD4 cell count or
alcohol use. Study authors suggest that in co-
infected persons, consideration should be given
to starting HAART earlier (when CD4 cells are
<500) to slow HCV-related fibrosis. 
NATAP - www.natap.org
Inside News
Resources
The CDC's Advisory Committee on
Immunization Practices (ACIP) revised
guidelines for the Prevention and Control of
Influenza:
www.cdc.gov/mmwr/preview/mmwrhtml/
rr53e430a1.htm
HIV and Hepatitis PDF reports formatted for
print:
www.hivandhepatitis.com/reports/2003list.html 
National Institutes of Health Consensus
Development Conference Statement -
Management of Hepatitis C: June 10-12,
2002:
http://consensus.nih.gov/cons/116/
091202116cdc_statement.htm
National Center for Infectious Diseases, Viral
Hepatitis C
www.cdc.gov/ncidod/diseases/hepatitis/c/plan/
Implement.htm
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through December 31, 2004. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. The percentage of chronic liver disease in the U.S. that can
be attributed to hepatitis C virus (HCV) is approximately:
a) 20
b) 40
c) 60
d) 80
2. Sustained virologic response (SVR) is defined as:
a) undetectable HCV RNA 24 weeks after completion of 
therapy
b) undetectable HCV RNA 12 weeks after completion of 
therapy
c) a decline in the HCV viral load of at least 2 log from 
baseline after 12 of therapy
d) a decline in the HCV viral load of at least 2 log from 
baseline after 24 of therapy
3. Which statement best supports the argument that an early viral
response (EVR) should be used as an individualized tool rather
than a hard and fast rule for terminating therapy:
a) A recent economic study has shown that the use of 
EVR decreased costs by 45%.
b) Patients not achieving an EVR have almost no chance 
of achieving an SVR.
c) Some patients may obtain histologic benefit from HCV 
therapy even if they do not reach early or sustained virologic 
responses.
d) None of the above
4. Which of the following statements is supported by the litera-
ture:
a) Among those who are HIV-infected, the rate of 
progression of HCV-related fibrosis is slowed.
b) As compared to those who are not infected with HCV, 
HIV-infected persons who are also HCV-infected experience 
a markedly increased rate of decline of CD4 cells. 
c) Among those who are HIV-infected, the rate of 
progression of HCV related fibrosis is accelerated.
d) Among those who are HCV-infected, co-infection with HIV 
markedly decreases the likelihood of achieving an EVR and 
a SVR.
5. The ethnic group that has the highest rate of HCV genotype 1
infection is:
a) Hispanics
b) Caucasions
c) Asian/Pacific Islanders
d) African-Americans
6. Policies and procedures for HCV care and treatment in the
correctional setting varies significantly from state to state. 
True or False.
a) True
b) False
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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